Interventional Glaucoma

Inder Paul Singh, MD, speaks to the potential of artificial intelligence (AI) in the management of the glaucoma disease state as well as the current challenges of drug delivery in treating patients with glaucoma.

John Berdahl, MD, discusses a non-surgical, non-drug treatment for glaucoma approved by the FDA in 2024. The pump uses negative pressure to lower eye pressure by an average of 39% in clinical trials, with a good safety profile.

Patients’ near visual needs is important when prescribing medications for glaucoma treatment

Real-world scenarios showcase a shift in treatment paradigms

Through its ophthalmic program, Mercy Ships provides critical eye surgeries and trains local professionals, ensuring sustainable eye care for the future.

Recipients will be awarded $100,000 to support a collaborative project related to glaucoma

The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical medications by providing 24/7 release of medication.

Himani Goyal, MD, discusses a complex glaucoma case involving persistent intraocular pressure elevation despite multiple treatment procedures, focusing on advanced management strategies and decision-making for challenging cases.

Himani Goyal, MD, explores a case of glaucoma treated with an intracameral implant, evaluating its efficacy in managing intraocular pressure and its role in optimizing long-term glaucoma care.

Himani Goyal, MD, discusses a case of cataracts and minimally invasive glaucoma surgery (MIGS) combination, highlighting the benefits of this approach in managing both cataracts and glaucoma in a single procedure for improved patient outcomes.

The long-term analysis show clinically and statistically significant reductions in intraocular pressure through up to 36 months postoperatively.

The campaign will spotlight educational resources and share stories of individuals and families living with glaucoma to raise awareness and encourage proactive eye health management.

Himani Goyal, MD, assesses the benefits of proactive glaucoma management through interventional procedures beyond traditional treatments, focusing on treatment customization based on factors such as visual potential, glaucoma staging, IOP targets, comorbid conditions, and patient preferences.

These resources include downloadable fact sheets, glaucoma financial assistance resources, shareable social media graphics, and a dedicated webpage.

Lana Rifkin, MD, a uveitis specialist at Ophthalmic Consultants of Boston, shared insights into her work and her role as committee chair of the uveitis section for the upcoming EnVision Summit, which will be held from February 14 to 17, 2025, at the Caribe Hilton San Juan in Puerto Rico.

Iantrek’s CREST Registry reports 1-year outcomes for a bio-interventional glaucoma treatment, demonstrating significant IOP reduction, medication reduction, and a favorable safety profile, offering a promising new approach for open-angle glaucoma management.

Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating glaucoma, particularly in conjunction with cataract surgery.

According to researchers, GPT-4o demonstrates potential in generating comprehensive differential glaucoma diagnoses but falls short in primary diagnostic accuracy, underscoring its role as a complementary tool rather than a standalone diagnostic solution.

PolyActiva’s phase 2 clinical trial of its PA5108 glaucoma implant met efficacy and safety end points, demonstrating more than 20% reduction in IOP. The biodegradable implant offers sustained drug delivery for up to 26 weeks, addressing challenges of patient adherence and improving glaucoma treatment outcomes.

While studies of obesity and tobacco and alcohol consumption showed that many chronic diseases are affected by the factors being studied, none had mentioned an effect on glaucoma progression.

SpyGlass Pharma completed enrollment in a Phase 1/2 trial evaluating its drug delivery platform for glaucoma and ocular hypertension. Designed for implantation during cataract surgery, the platform delivers bimatoprost to lower intraocular pressure for up to 3 years.

This retrospective cohort study was designed to provide further information on the association between BP parameters and VF progression over time.

Program director and co-founder Bonnie An Henderson, MD, sits down with Ophthalmology Times to talk about how the annual conference is a unique blend of cutting-edge science, professional growth, and community. The 2025 conference will take place February 14 to 17 at the Caribe Hilton San Juan, in Puerto Rico.

While anxiety and depression may cause vision loss, physicians can offer hope

Moon Jeong Lee, MD, shares how volunteering in geriatric care shaped her career path.

Ripple will lead preclinical development of RTC-620 while AbbVie will lead the clinical and commercialization activities upon exercise of option-to-license agreement.

According to the company, topline results will be presented at the 2024 American Academy of Ophthalmology Annual Meeting, being held October 18 to 21 in Chicago, Illinois.

German researchers found that their study results suggest that the effect of glaucoma on the elapsed time depends on disease progression. This uncertainty during everyday navigation tasks may adversely affect patients’ quality of life.

Common glaucoma treatments may worsen ocular surface disease and meibomian gland dysfunction, leading to discomfort, redness, and even poor treatment compliance.

Push to identify biomarkers for earlier diagnosis, new therapeutic targets.